eli lilly retatrutide study Lilly's tirzepatide showed positive results in late-stage trial as treatment for heart failure retatrutide expanded access program eli

2021 Mar 18;384(11):9891002

This may sound controversial to some, but we have been sounding the alarm on this for quite some time

Patients experiencing significant or persistent hair shedding should discuss this with their clinician

Drug Design, Development and Therapy

Anxiety was the most central symptom within the symptom network at T1 (Strength = 2.134, Closeness = 0.127, EI = 2.134), while depression held the central position at T2 (Strength = 2.595, Closeness = 0.157, EI = 2.595), T3 (Strength = 2.689, Closeness = 0.161, EI = 2.689), and T4 (Strength = 2.789, Closeness = 0.172, EI = 2.789)

Kind Patches marketing materials include several claims that could violate ASA guidelines: 92.3% of participants reported fewer cravings (unsubstantiated efficacy claim) Before/after style testimonials without clinical backing Implications that patches work similarly to prescription medications Claims about supporting GLP-1 production without evidence The ASA considers testimonials making medical claims as advertising, regardless of whether theyre genuine customer experiences